{
    "clinical_study": {
        "@rank": "19899", 
        "acronym": "ATLAS", 
        "arm_group": {
            "arm_group_label": "Simtuzumab", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive simtuzumab every 7 days"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in\n      participants with Idiopathic Pulmonary Fibrosis (IPF) who had previously participated in\n      Gilead clinical trial AB0024-201."
        }, 
        "brief_title": "Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF)", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis", 
                "Idiopathic Pulmonary Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previous participation in Phase 1 Gilead clinical trial\n\n          -  Diagnosis of Idiopathic Pulmonary Fibrosis\n\n          -  Females of childbearing potential and non-vasectomized males must agree to use highly\n             effective methods of contraception\n\n          -  Females must discontinue nursing\n\n          -  Comply with study requirements\n\n          -  Have adequate organ function\n\n        Exclusion Criteria:\n\n          -  History or evidence of clinically significant disorder, condition or disease that\n             would pose a risk or interfere with the study\n\n          -  Pregnant or lactating\n\n          -  Clinically significant heart, hepatic or renal disease\n\n          -  History of cancer within 5 years of screening\n\n          -  Infection that is not controlled despite antibiotics or other treatment\n\n          -  History of bleeding diathesis within the last 6 months of Day 1\n\n          -  Known history of Human Immunodeficiency Virus, hepatitis B or C\n\n          -  Concern's for subjects compliance\n\n          -  Other conditions that might put the subject at high risk for treatment complications\n             or reduce the chance to obtain data required\n\n          -  Placed on a lung transplant list\n\n          -  Previous participation in an Idiopathic Pulmonary Fibrosis clinical trial other than\n             for Gilead Sciences -6624"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759511", 
            "org_study_id": "GS-US-322-0206"
        }, 
        "intervention": {
            "arm_group_label": "Simtuzumab", 
            "description": "Simtuzumab 125 mg/mL administered subcutaneously", 
            "intervention_name": "Simtuzumab", 
            "intervention_type": "Drug", 
            "other_name": "GS-6624"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Idiopathic", 
            "Pulmonary", 
            "Fibrosis", 
            "IPF"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85012"
                    }, 
                    "name": "Arizona Pulmonary Specialists, Ltd."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Thomas O'Riordan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with Adverse Events as a measure for safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Year 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759511"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "FVC is a pulmonary function test, and is defined as the volume of air that can forcibly be blown out after taking a full breath.", 
                "measure": "Change in Forced Vital Capacity (FVC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }, 
            {
                "description": "DLCO is a measurement to determine the extent to which oxygen passes from the air sacs of the lungs into the blood.", 
                "measure": "Change in Diffusing Lung Capacity for Carbon Monoxide (DLCO)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }, 
            {
                "description": "All-cause mortality will be assessed as a percentage of participants who die from any cause.", 
                "measure": "All-cause mortality", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }, 
            {
                "measure": "Change in serum LOXL2 levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}